Multi-functionalized graphene oxide complex as a plasmid delivery system for targeting hepatocellular carcinoma therapy

Wang, Chunyang; Wang, Xiaoqin; Lu, Tiecheng; Liu, Fangshi; Guo, Baofeng; Wen, Naiyan; Du, Yanwei; Lin, Hang; Tang, Jun; Zhang, Ling

doi:10.1039/c5ra21475k

Cited by 22 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Folic acid (FA)-modified GO was used as a novel vector to increase gene delivery efficiency and successfully loaded the SI-Stas3 gene into cells. 30 In our previous work, we proved that GO can deliver siRNA into cells and downregulate the expression of the desired gene. This study investigated the potential of a modified GO nanocarrier for co-delivery of siRNA and DOX for enhanced cancer therapy.…”

Section: Introductionmentioning

confidence: 93%

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Sun¹,

Wang²,

Cui³

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundGraphene oxide (GO) has attracted intensive interest in biological and medical fields in recent years due to its unique physical, chemical, and biological properties. In our previous work, we proved that GO could deliver small interfering RNA (siRNA) into cells and downregulate the expression of the desired gene.MethodsThis study investigated the potential of a modified GO nanocarrier for co-delivery of siRNA and doxorubicin (DOX) for enhanced cancer therapy. Fourier transform infrared spectroscopy, laser particle size analyzer, UV-visible spectroscopy, gel electrophoresis retardation, and in vitro release assay were studied.ResultsThe results of real-time polymerase chain reaction revealed that the expression of vascular endothelial growth factor (VEGF) mRNA was decreased 46.84%±3.72% (mean ± SD). Enzyme-linked immunosorbent assay indicated that the expression of VEGF protein was down-regulated to 52.86%±1.10% (mean ± SD) in vitro. In vivo tumor growth assay GO-poly-l-lysine hydrobromide/folic acid (GPF)/DOX/siRNA exhibited gene silencing and tumor inhibition (66.95%±2.35%, mean ± SD) compared with naked siRNA (1.62%±1.47%, mean ± SD) and DOX (33.63%±5.85%, mean ± SD). GPF/DOX/siRNA exhibited no testable cytotoxicity.ConclusionThe results indicated that co-delivery of siRNA and DOX by GPF could be a promising application in tumor clinical therapy.

show abstract

Section: Introductionmentioning

confidence: 93%

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Sun¹,

Wang²,

Cui³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…The appearance of the peaks at 3408 cm À1 , 1731 cm À1 and 1161 cm À1 in the spectrum of GOBC, were attributed to the stretching vibrations of N-H, C]O, and C-N bonds, respectively, of methacrylate groups. 30,41,42,45 The appearance of a new peak at 1652 cm À1 corresponded to stretching vibrations of NH-CO bond, which was formed by the coupling reaction of CGO with the AEM. 30 TGA and DSC measurements were performed to investigate the thermal stability of GO, CGO, and GOBC.…”

Section: Synthesis and Characterization Of Go Cgo Gobcmentioning

confidence: 99%

Mechanically tough and highly stretchable poly(acrylic acid) hydrogel cross-linked by 2D graphene oxide

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 12 , 14 , 15 In recent years, GO as a carrier for siRNA has shown broad prospects. For instance, Wang et al 16 developed a GO-based gene delivery system by covalently conjugating polyethylene glycol (PEG) and polyethylenimine (PEI) to GO nanosheet to improve its stability and gene transfection efficiency and reduce its cytotoxicity in serum conditions. With such superior phototherapy-enhanced gene delivery ability, the fabricated NGO-PEG-PEI has demonstrated to be a promising candidate for combined gene and photothermal therapies.…”

Section: Introductionmentioning

confidence: 99%

Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo

Wang

Sun

Cui

et al. 2018

DDDT

View full text Add to dashboard Cite

BackgroundThe success of gene therapy is mostly dependent on the development of gene carrier. Graphene oxide (GO) possesses excellent aqueous solubility and biocompatibility, which is important for its biochemical and medical applications. Our previous work proved that GO can deliver siRNA into cells efficiently and downregulate the expression of desired protein.MethodsIn this study, a novel delivery carrier, GO-R8/anti-HER2 (GRH), was developed by conjugating octaarginine (R8) and anti-HER2 antibody with GO as a tumor active-targeting vector for survivin-siRNA delivery.ResultsGRH/survivin-siRNA formed nanoglobes of 195±10 nm in diameter. Real-time polymerase chain reaction analysis revealed that survivin messenger RNA expression showed a 42.4%±2.69% knockdown. The expression of survivin protein was downregulated to 50.86%±2.94% in enzyme-linked immunosorbent assay. In MTT tests, GRH exhibited no testable cytotoxicity. In vivo, GRH/survivin-siRNA showed gene silencing and inhibition of tumor growth.ConclusionThe in vitro and in vivo results consistently demonstrated that GRH/survivin-siRNA has potential to be an efficient gene silencing carrier for siRNA delivery in cancer therapy.

show abstract

Multi-functionalized graphene oxide complex as a plasmid delivery system for targeting hepatocellular carcinoma therapy

Abstract: A novel and efficient graphene-based gene delivery vector was prepared, the effect of changing the PEI content on the size, stability and transfection efficiency were investigated.

Cited by 22 publications

References 47 publications

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Mechanically tough and highly stretchable poly(acrylic acid) hydrogel cross-linked by 2D graphene oxide

Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo

Contact Info

Product

Resources

About